Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis

References

• Brown RH, Al-Chalabi A, Longo DL. Amyotrophic lateral sclerosis. N Engl J Med. 2017 Jul 13;377(2):162–172. doi: 10.1056/NEJMra1603471
   PubMed Web of Science ®Google Scholar
• Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009 Oct;10(5–6):310–323.
   PubMed Web of Science ®Google Scholar
• Lechtzin N, Cudkowicz ME, de Carvalho M, et al. Respiratory measures in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5–6):321–330.
   PubMed Web of Science ®Google Scholar
• Chio A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020 May 1;167:107986. doi: 10.1016/j.neuropharm.2020.107986
   PubMed Web of Science ®Google Scholar
• Jiang J, Wang Y, Deng M. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. Front Pharmacol. 2022;13:1054006. doi: 10.3389/fphar.2022.1054006
   PubMed Web of Science ®Google Scholar
• Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022 Sep 22;387(12):1099–1110. doi: 10.1056/NEJMoa2204705
   PubMed Web of Science ®Google Scholar
• Achtert K, Kerkemeyer L. The economic burden of amyotrophic lateral sclerosis: a systematic review. Eur J Health Econ. 2021 Nov;22(8):1151–1166. doi: 10.1007/s10198-021-01328-7
   PubMed Web of Science ®Google Scholar
• Xu L, Liu T, Liu L, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020 Apr;267(4):944–953.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999 Oct 31;169(1–2):13–21. doi: 10.1016/S0022-510X(99)00210-5
   PubMed Web of Science ®Google Scholar
• Tramacere I, Dalla Bella E, Chio A, et al. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1180–1185.
   PubMed Web of Science ®Google Scholar
• Goutman SA, Hardiman O, Al-Chalabi A, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022 May;21(5):480–493.
   PubMed Web of Science ®Google Scholar
• Chio A, Hammond ER, Mora G, et al. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):38–44.
   PubMed Web of Science ®Google Scholar
• Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012 Mar;135(Pt 3):847–852.
   PubMed Web of Science ®Google Scholar
• Thakore NJ, Lapin BR, Kinzy TG, et al. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7–8):483–494.
   PubMed Web of Science ®Google Scholar
• Balendra R, Jones A, Jivraj N, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS functional rating scale. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3–4):279–284.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Chio A, Merrill C, et al. Clinical staging in amyotrophic lateral sclerosis: analysis of edaravone study 19. J Neurol Neurosurg Psychiatry. 2021 Feb;92(2):165–171.
   PubMed Web of Science ®Google Scholar
• Gebrehiwet P, Meng L, Rudnicki SA, et al. MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3–4):304–310.
   PubMed Web of Science ®Google Scholar
• Nikitin D, Makam AN, Suh K, et al. The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: a summary from the institute for clinical and economic review’s midwest comparative effectiveness public advisory council. J Manag Care Spec Pharm. 2023 Feb;29(2):216–221.
   PubMed Web of Science ®Google Scholar
• Thakore NJ, Pioro EP, Udeh BL, et al. A cost-effectiveness framework for amyotrophic lateral sclerosis, applied to riluzole. Value Health. 2020 Dec;23(12):1543–1551.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health Common Drug Review. Pharmacoeconomic review report edaravone (RADICAVA) (MItsubishi Tanabe Pharma Corporation). Indication: for the treatment of amyotrophic lateral sclerosis (ALS). Apr 2019 [cited 2023 Jun 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542526/pdf/Bookshelf_NBK542526.pdf
   Google Scholar
• Naimark DM, Bott M, Krahn M. The half-cycle correction explained: two alternative pedagogical approaches. Med Decis Making. 2008 Sep;28(5):706–712. doi: 10.1177/0272989X08315241
   PubMed Web of Science ®Google Scholar
• Kim DD, Wilkinson CL, Pope EF, et al. The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):615–623.
   PubMed Web of Science ®Google Scholar
• Moore A, Young CA, Hughes DA. Health utilities and costs for motor neurone disease. Value Health. 2019 Nov;22(11):1257–1265. doi: 10.1016/j.jval.2019.05.011
   PubMed Web of Science ®Google Scholar
• Atassi N, Berry J, Shui A, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719–25. doi: 10.1212/WNL.0000000000000951
   PubMed Web of Science ®Google Scholar
• Castrillo-Viguera C, Grasso DL, Simpson E, et al. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11(1–2):178–180. doi: 10.3109/17482960903093710
   PubMed Web of Science ®Google Scholar
• Tzeplaeff L, Wilfling S, Requardt MV, et al. Current state and future directions in the therapy of ALS. Cells. 2023 May 31;12(11):1523. doi: 10.3390/cells12111523
   PubMed Web of Science ®Google Scholar
• Franco C, Little RJA, Louis TA, et al. Comparative study of confidence intervals for proportions in complex sample surveys. J Surv Stat Methodol. 2019 Sep;7(3):334–364.
   PubMed Web of Science ®Google Scholar
• Hazra A. Using the confidence interval confidently. J Thorac Dis. 2017 Oct;9(10):4125–4130. doi: 10.21037/jtd.2017.09.14
   PubMed Web of Science ®Google Scholar
• Attema AE, Brouwer WBF, Claxton K. Discounting in Economic Evaluations. PharmacoEconomics. 2018 Jul;36(7):745–758. doi: 10.1007/s40273-018-0672-z
   PubMed Web of Science ®Google Scholar
• Gebrehiwet P, Eguale T, Segal A, et al. PDB27 the diabetes prevention program (dpp) quality of well being (qwb) utility measures and missing data considerations: available case analysis (aca) vs. manski lower and upper bounds (lmb and umb) results for utilities and quality adjusted life years (qalys). Value Health. 2020;23:S112–113. doi: 10.1016/j.jval.2020.04.215
   Google Scholar
• Gidwani R, Russell LB. Estimating transition probabilities from published evidence: a tutorial for decision modelers. PharmacoEconomics. 2020 Nov;38(11):1153–1164. doi: 10.1007/s40273-020-00937-z
   PubMed Web of Science ®Google Scholar
• Drummond MFS, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford, UK: Oxford University Press; 2015.
   Google Scholar
• Vemer P, Corro Ramos I, van Voorn GA, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. PharmacoEconomics. 2016 Apr;34(4):349–61.
   PubMed Web of Science ®Google Scholar
• Kjaeldgaard AL, Pilely K, Olsen KS, et al. Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study. BMC neurol. 2021 Apr 17;21(1):164. doi: 10.1186/s12883-021-02187-8
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Visser CE, Bossuyt PM, et al. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. J Neurol Sci. 1997 Oct;152(Suppl 1):S10–7.
   PubMed Web of Science ®Google Scholar
• Punjani R, Larson TC, Wagner L, et al. Survival and epidemiology of amyotrophic lateral sclerosis (ALS) cases in the Chicago and Detroit metropolitan cohort: incident cases 2009-2011 and survival through 2018. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3–4):203–211.
   PubMed Web of Science ®Google Scholar
• Hartmaier SL, Rhodes T, Cook SF, et al. Qualitative measures that assess functional disability and quality of life in ALS. Health Qual Life Outcomes. 2022 Jan 21;20(1):12. doi: 10.1186/s12955-022-01919-9
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Stahl DR, et al. Comparison of the King’s and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3–4):227–232.
   PubMed Web of Science ®Google Scholar
• Genge A, Chio A. The future of ALS diagnosis and staging: where do we go from here? Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3–4):165–174. doi: 10.1080/21678421.2022.2150555
   PubMed Web of Science ®Google Scholar
• Polak TB, Cucchi DGJ, Darrow JJ, et al. Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020. BMJ Open. 2022 Apr 8;12(4):e058279. doi: 10.1136/bmjopen-2021-058279
   PubMed Web of Science ®Google Scholar
• Gebrehiwet P, Meng L, Rudnicki SA, et al. Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS. J Med Econ. 2023 Jan;26(1):488–493.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health Common Drug Review. CADTH reimbursement review report sodium phenylbutyrate-ursodoxicoltaurine (Albrioza) (Amylyx Canada). Indication: for the treatment of amyotrophic lateral sclerosis (ALS). Oct 2022. [cited 2023 Aug 30]. Available from https://www.cadth.ca/sites/default/files/DRR/2022/SR0711-Albrioza.pdf
   Google Scholar
• Ginsberg G, Lowe S. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature. PharmacoEconomics. 2002;20(6):367–387. doi: 10.2165/00019053-200220060-00002
   PubMed Web of Science ®Google Scholar
• Garrison LP, Jackson T, Paul D, et al. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019 Jul;25(7):793–799.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, de Jongh AD, Nikolakopoulos S, et al. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2021 May;22(3–4):300–307.
   PubMed Web of Science ®Google Scholar
• Dalla Bella E, Bersano E, Antonini G, et al. The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Brain. 2021 Oct 22;144(9):2635–2647. doi: 10.1093/brain/awab167
   PubMedGoogle Scholar
• ClinicalTrials.gov. Phase III trial of AMX0035 for amyotrophic lateral sclerosis treatment (Phoenix), 2023 Dec 19. Available from: https://clinicaltrials.gov/study/NCT05021536
   Google Scholar
• Shefner JM, Al-Chalabi A, Andrews JA, et al. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5–6):523–534.
   PubMed Web of Science ®Google Scholar
• Schonfelder E, Osmanovic A, Muschen LH, et al. Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany. Orphanet J Rare Dis. 2020 Jun 12;15(1):149. doi: 10.1186/s13023-020-01413-9
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Meurgey JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018 May;17(5):416–422.
   PubMed Web of Science ®Google Scholar